Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
+ 371 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Locations: - Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Alaska Breast Care and Surgery LLC — Anchorage, Alaska
- Alaska Oncology and Hematology LLC — Anchorage, Alaska
+ 338 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Locations: - Banner MD Anderson Cancer Center — Gilbert, Arizona
- Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
+ 331 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Locations: - Providence Alaska Medical Center — Anchorage, Alaska
- AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
+ 135 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRP…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136650
Locations: - The University of Arizona Cancer Center - North Campus ( Site 0073) — Tucson, Arizona
- CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 0120) — Irvine, California
- UCLA Hematology/Oncology - Santa Monica ( Site 0044) — Los Angeles, California
+ 60 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Locations: - University of California at San Diego — La Jolla, California
- Cedars Sinai Medical Center — Los Angeles, California
- Ronald Reagan UCLA Medical Center — Los Angeles, California
+ 51 more sites in the U.S.
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Locations: - Ironwood Cancer & Research Centers — Chandler, Arizona
- Ironwood Cancer & Research Centers — Gilbert, Arizona
- Palo Verde Hematology Oncology — Glendale, Arizona
+ 36 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA ta…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06780670
Locations: - Honor Health Research Institute — Scottsdale, Arizona
- VA Greater LA Healthcare System — Los Angeles, California
- VA Palo Alto Health Care System — Palo Alto, California
+ 32 more sites in the U.S.
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Locations: - University of Alabama Birmingham Hospital — Birmingham, Alabama
- Mayo Clinic- Phoenix — Phoenix, Arizona
- Arkansas Urology Research Center, LLC — Little Rock, Arkansas
+ 26 more sites in the U.S.
Phase 3 Recruiting Industry
This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicine…
Sponsor: BioNTech SE
NCT ID: NCT07365995
Locations: - Sansum Clinic — Santa Barbara, California
- Rocky Mountain Cancer Centers — Aurora, Colorado
- Florida Cancer Specialists- Fort Myers — Fort Myers, Florida
+ 18 more sites in the U.S.
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Locations: - VA Long Beach Healthcare System, Long Beach, CA — Long Beach, California
- VA Greater Los Angeles Healthcare System, West Los Angeles, CA — West Los Angeles, California
- Washington DC VA Medical Center, Washington, DC — Washington D.C., District of Columbia
+ 17 more sites in the U.S.
Phase 3 Recruiting Industry
Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamid…
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT07723248
Locations: - SSAK Partners, LLC — Coral Springs, Florida
- First Urology PSC — Jeffersonville, Indiana
- Cancer And Hematology Centers Of Western Michigan — Holland, Michigan
+ 8 more sites in the U.S.